Figure 2
Pharmacological properties of R723 and its effects on peripheral monocytes. (A, B) Pharmacological profile of R723 in plasma and spinal cord tissue after single-dose administration by oral gavage to 120-day-old female mSOD1G93A mice. Concentration of the compound at the indicated time points was quantified by LC/MS/MS assay. (C, D) Effects of R723 treatment on the proportion of CD11b + or Ly6c + cells in peripheral blood. mSOD1G93A mice (120 days old) were orally administered with vehicle or R723 (70 mg/kg) for 4 days. Blood were harvested, and the proportions of CD11b + and Ly6c + cells were evaluated by FACS. (C) The proportion of CD11b + monocytes was significantly reduced in peripheral blood of R723-treated mSOD1G93A mice. (D) Four-day treatment with R723 reduced the proportion of Ly6c + CD11b + monocytes in peripheral blood. In panels (C) and (D), n = 3 for vehicle-treated mice, and n = 4 for R723 treated mice. Data are expressed as means ± SEM. *P < 0.05, Mann-Whitney U-test.